Data gathered: January 21
AI Stock Analysis - Cabaletta Bio (CABA)
Analysis generated December 2, 2024. Powered by Chat GPT.
Cabaletta Bio is a clinical-stage biotechnology company focused on developing and delivering T cell therapies that address the immune dysregulation underlying autoimmune diseases. Founded on the expertise of pioneers in autoimmunity and cell therapy, the company seeks to transform the lives of patients with its targeted approaches. Although the company is in the developmental stages, it shows great promise in the biotech space, an area known for long R&D cycles and significant investor interest.
Stock Alerts - Cabaletta Bio (CABA)
 |
Cabaletta Bio | January 21 Price is down by -5.8% in the last 24h. |
|
Cabaletta Bio | January 17 Price is up by 11.9% in the last 24h. |
|
Cabaletta Bio | January 16 Price is up by 5.6% in the last 24h. |
|
Cabaletta Bio | January 15 Price is up by 8.7% in the last 24h. |
Alternative Data for Cabaletta Bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 68 | Sign up | Sign up | Sign up |
| Webpage traffic | 18,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,634 | Sign up | Sign up | Sign up |
| Twitter Followers | 475 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 171 | Sign up | Sign up | Sign up |
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
| Price | $2.60 |
| Target Price | Sign up |
| Volume | 1,570,000 |
| Market Cap | $134M |
| Year Range | $1.87 - $12.88 |
| Dividend Yield | 0% |
| Analyst Rating | 78% buy |
| Industry | Biotechnology |
In the news
 |
17,605 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Avanza Fonder ABJanuary 21 - ETF Daily News |
|
Barclays PLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA)January 21 - ETF Daily News |
|
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024January 20 - ETF Daily News |
|
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $24.38 Consensus Target Price from BrokeragesJanuary 20 - ETF Daily News |
 |
Cabaletta Bio’s (CABA) “Buy” Rating Reiterated at HC WainwrightJanuary 19 - ETF Daily News |
 |
Cabaletta Bio announces strategic priorities, anticipated milestones for 2025January 13 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 6.8M | -6.8M | -31M | -33M | -0.620 |
| Q2 '24 | 0 | 6.9M | -6.9M | -28M | -30M | -0.560 |
| Q1 '24 | 0 | 6.3M | -6.3M | -25M | -28M | -0.510 |
| Q4 '23 | 4M | 5.9M | -5.9M | -21M | -23M | -0.460 |
| Q3 '23 | 0 | 4.9M | -4.9M | -16M | -19M | -0.370 |
Insider Transactions View All
| Binder Gwendolyn filed to sell 20,000 shares at $20.3. January 19 '24 |
| Binder Gwendolyn filed to sell 20,700 shares at $19.5. January 19 '24 |
| Binder Gwendolyn filed to sell 20,000 shares at $22.2. December 19 '23 |
| Binder Gwendolyn filed to sell 23,132 shares at $21.8. December 19 '23 |
| Binder Gwendolyn filed to sell 27,458 shares at $17.4. November 21 '23 |
Similar companies
Read more about Cabaletta Bio (CABA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Cabaletta Bio?
The Market Cap of Cabaletta Bio is $134M.
What is the current stock price of Cabaletta Bio?
Currently, the price of one share of Cabaletta Bio stock is $2.60.
How can I analyze the CABA stock price chart for investment decisions?
The CABA stock price chart above provides a comprehensive visual representation of Cabaletta Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cabaletta Bio shares. Our platform offers an up-to-date CABA stock price chart, along with technical data analysis and alternative data insights.
Does CABA offer dividends to its shareholders?
As of our latest update, Cabaletta Bio (CABA) does not offer dividends to its shareholders. Investors interested in Cabaletta Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cabaletta Bio?
Some of the similar stocks of Cabaletta Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.